^
Association details:
| Biomarker: | CD276 underexpression + EGFR mutation |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug Class: | EGFR inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
B7-H3 is eligible for predicting clinical outcomes in lung adenocarcinoma patients treated with EGFR tyrosine kinase inhibitors
Published date:
05/20/2022
Excerpt:
In the subgroups of B7-H3 high and low expression, the ORR were 16.0% (4/25) and 74.2% (23/31) (p<0.001), and the DCR were 36.0% (9/25) and 87.1% (27/31) (p<0.001), respectively….B7-H3 may serve as a potential biomarker to predict clinical outcomes in EGFR-mutated LUAD patients treated with first-line EGFR-TKIs.
DOI:
https://doi.org/10.1186/s12957-022-02634-x
